Spigel DR, Faivre-Finn C, Gray JE, Vicente D, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2022 Feb 2:JCO2101308. doi: 10.1200/JCO.21.01308.
PMID: 35108059